Genmab — November 2018
-
@bulder, var det ikke AMGN420 du så som en konkurrent til Dara?? Ser sgu ikke sådan ud
-
eller husker jeg forkert?
-
øh, det tror jeg du gør. Jeg har netop fremhævet de bispecifikke antistoffer som mulige kombinationspartnere i stedet for konkurrenter. På samme måde som nogen førhen så check point blokkerne som konkurrenter. De har vist sig at være interessante makkere i stedet.
-
ok
-
God morgen.
-
Kører J&J ikke forsøg med Dara i RA. ? . Måske derfor de har droppet dette da Dara måske ser bedre ud. https://www.fiercebiotech.com/biotech/johnson-johnson-drops-ose-s-rheumatoid-arthritis-drug?mkt_tok=eyJpIjoiTlRkaE9Ea3daV0kyT0dNeCIsInQiOiJKSEs0bENUUlU2NHJEN29oVmYyTktBMXZrdkFiQXJtSlwvZWR4dkxLYlVWMm5iN1RmN2Zha2dvRjFLYVwvUUM0Q1E5WXZjaUtKOFROcjlhTWhaRmdINWx5dnFSanR6ZSt0QlBkdmlpd0dNV0FPcHZMUTRjQUZQWFhpb2RGZWJXU3puIn0%3D&mrkid=41140432
-
Kan ikke huske om de er startet med Dara har effekt https://www.ncbi.nlm.nih.gov/pubmed/29720240
-
but at the moment "BCMA in the spotlight as ASH abstracts drop" http://www.pmlive.com/pharma_news/bcma_in_the_spotlight_as_ash_abstracts_drop_1258442 , so as Sukkeralf said, a bit disappointing JNJ has nothing at ASH on the BCMA CD3
-
34 studies of RA enrolling by invitation. https://www.clinicaltrials.gov/ct2/results?recrs=f&cond=Rheumatoid+Arthritis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind